一品红 (300723)
ApicHope Pharmaceutical Group Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 45169.28
- Circulating A-Shares(W): 41766.72
- Earnings Per Share(RMB): -0.3013
- Net Assets Per Share(RMB): 3.8761
- Operating Revenue(W RMB): 81400.33
- Total Profit(W RMB): -15573.20
- Net Profit Attributable to Parent(W RMB): -13608.32
- Net Profit Growth Rate(%): 44.80
- Weighted Return on Equity(%): -7.5200
- Operating Cash Flow Per Share(RMB): -0.0260
- Undistributed Profit Per Share(RMB): 1.3093
- Capital Reserve Per Share(RMB): 1.5289
2. Main Business
The main business covers:
- Research, development, production, and sales of pharmaceuticals
3. Company Basic Information
- Company Name: ApicHope Pharmaceutical Group Co., Ltd.
- Listing Date: 2017-11-16
- Industry: Pharmaceutical Manufacturing
- Address: Floors 15-19, Yunrun Building, No. 27 Huanyu 1st Road, Guangzhou International Bio-Island, Huangpu District, Guangzhou City, Guangdong Province
- Website: www.gdyph.com,www.apichope.com
- Company Profile: ApicHope Pharmaceutical Group Co., Ltd. was established on February 4, 2002, with a registered capital of RMB 5 million. It was approved for establishment by the Guangdong Provincial Administration for Industry and Commerce on the same day. The issuer was transformed from ApicHope Co., Ltd. into a joint-stock company. On October 26, 2015, ApicHope Co., Ltd. held a shareholders' meeting and resolved to convert the company into a joint-stock company based on the audited net assets of RMB 139,815,706.63 as of August 31, 2015, at a ratio of 1:0.8583, resulting in a total share capital of 120 million shares, and renamed as “ApicHope Pharmaceutical Co., Ltd.” On December 1, 2015, the Guangdong Provincial Administration for Industry and Commerce approved the establishment of the joint-stock company, and the company obtained the Business License with the Unified Social Credit Code 914400007361542488.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guangdong Guangrun Group Co., Ltd. | General Legal Person | 18360.00 | 43.96 |
| 2 | Guangzhou Fuzi Investment Management Center (Limited Partnership) | General Legal Person | 2430.00 | 5.82 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 414.96 | 0.99 |
| 4 | GF Healthcare Equity Securities Investment Fund Class A | Fund | 304.52 | 0.73 |
| 5 | Fullgoal Precision Healthcare Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 281.13 | 0.67 |
| 6 | E Fund Healthcare Industry Hybrid Securities Investment Fund Class A | Fund | 267.11 | 0.64 |
| 7 | E Fund Pharmaceutical & Biological Equity Securities Investment Fund Class A | Fund | 263.97 | 0.63 |
| 8 | Great Wall Pharmaceutical Industry Selection Hybrid Initiated Securities Investment Fund Class A | Fund | 180.99 | 0.43 |
| 9 | Invesco Great Wall Growth Star Equity Securities Investment Fund Class A | Fund | 171.42 | 0.41 |
| 10 | Fullgoal Healthcare Industry Hybrid Securities Investment Fund Class A | Fund | 148.01 | 0.35 |
5. Concept Sectors
- Biological Vaccines
- Infant & Child Concept
- Guangdong-Hong Kong-Macao Greater Bay Area
- Hepatitis Concept
- Innovative Drugs
- NVIDIA
- Weight Loss Drugs
- DeepSeek
- AI Healthcare
- Margin Trading & Securities Lending
- Share Repurchase Plan
- Consecutive Losses
- Recent Weakness
- Intensive Research
- ChiNext 300
- ChiNext Pharmaceuticals
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information